Brief: Aim Vaccine Submits Application For Clinical Trials For Absorbed Tetanus Vaccine
29/08/2024 17:46
Aug 29 (Reuters) - AIM Vaccine Co Ltd 6660.HK :
* OFFICIAL APPLICATION FOR CLINICAL TRIALS FOR ABSORBED
TETANUS
VACCINE SUBMITTED
* APPLICATION BEEN SUBMITTED TO NMPA OF CHINA
Further company coverage: 6660.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine